Analysts Issue Forecasts for ResMed’s Q3 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities researchers at William Blair decreased their Q3 2025 earnings per share estimates for shares of ResMed in a research note issued to investors on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider will post earnings per share of $2.32 for the quarter, down from their previous estimate of $2.37. The consensus estimate for ResMed’s current full-year earnings is $9.41 per share. William Blair also issued estimates for ResMed’s FY2026 earnings at $10.23 EPS.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

RMD has been the topic of a number of other research reports. Royal Bank of Canada increased their price target on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. The Goldman Sachs Group assumed coverage on ResMed in a research report on Thursday, January 16th. They issued a “buy” rating for the company. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Finally, Stifel Nicolaus initiated coverage on shares of ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 price target for the company. One analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Stock Up 0.7 %

Shares of NYSE RMD opened at $242.19 on Thursday. The business has a fifty day moving average of $239.82 and a two-hundred day moving average of $237.15. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The stock has a market cap of $35.55 billion, a PE ratio of 28.59, a PEG ratio of 1.69 and a beta of 0.70. ResMed has a 52-week low of $170.56 and a 52-week high of $263.05.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Thursday, February 13th. ResMed’s payout ratio is 25.03%.

Insider Activity

In other news, insider Justin Leong sold 6,160 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the sale, the insider now directly owns 21,718 shares of the company’s stock, valued at approximately $5,279,428.62. This represents a 22.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,094 shares of company stock worth $2,704,941. 0.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ResMed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. True Wealth Design LLC raised its position in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 110 shares during the period. Ashton Thomas Securities LLC bought a new position in ResMed during the 3rd quarter valued at about $34,000. BankPlus Trust Department purchased a new stake in shares of ResMed in the fourth quarter worth approximately $44,000. Rosenberg Matthew Hamilton purchased a new position in ResMed in the 4th quarter worth about $54,000. Finally, Capital Performance Advisors LLP purchased a new position in ResMed during the 3rd quarter worth $60,000. 54.98% of the stock is owned by institutional investors.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.